Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moderate Alcohol Clear all
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

NCT03371459
View directory record Official record
Conditions
Asthma
Interventions
AS MDI, Proventil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 20, 2026, 8:41 AM EDT
Withdrawn Phase 4 Interventional

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes

NCT04184609
View directory record Official record
Conditions
Asthma in Children, Dyspnea; Asthmatic, Obesity, Childhood
Interventions
Control, Albuterol
Other · Drug
Lead sponsor
Ohio State University
Other
Eligibility
9 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 20, 2026, 8:41 AM EDT
Not listed Phase 3 Interventional

Medication and Counseling for Controlled Drinking

NCT01115894
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Abuse
Interventions
Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy, Placebo
Drug · Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 20, 2026, 8:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Text-Based Messaging Strategies for Preventing Subsequent Problematic Alcohol Use

NCT06318975
View directory record Official record
Conditions
Alcohol Drinking, Binge Drinking, Text Messaging
Interventions
Brief Alcohol Intervention, Automated and Targeted Text Messages
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 8:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self-Affirmation: Construct Validity

NCT02317367
View directory record Official record
Conditions
Risk Reduction Behavior
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00027937
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

NCT02796651
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease - COPD
Interventions
Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 20, 2026, 8:41 AM EDT
Withdrawn Phase 1 Interventional

Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy

NCT01904786
View directory record Official record
Conditions
Newborn Hypoxic Ischemic Encephalopathy
Interventions
Melatonin, placebo
Drug
Lead sponsor
St. Louis University
Other
Eligibility
1 Hour to 8 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

NCT00200473
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 20, 2026, 8:41 AM EDT
Not listed Not applicable Interventional

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

NCT00295997
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
San Francisco, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 20, 2026, 8:41 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

NCT04480827
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 20, 2026, 8:41 AM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

NCT00002961
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 20, 2026, 8:41 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Alcohol-Related Hepatitis With Arginine

NCT00200746
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Arginine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Not applicable Interventional Results available

MOBILE Intervention in College Students With Elevated Blood Pressure

NCT05956925
View directory record Official record
Conditions
Hypertension
Interventions
Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 29 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

NCT01290874
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium, Salmeterol, Formoterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 20, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure

NCT00004854
View directory record Official record
Conditions
Heart Diseases
Interventions
Carvedilol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Months to 17 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 8:41 AM EDT
Completed No phase listed Observational

Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression

NCT00205075
View directory record Official record
Conditions
Hepatic Fibrogenesis, Hepatitis C
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 20, 2026, 8:41 AM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 8:41 AM EDT